MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Minerva Neurosciences Net Income 2011-2026 | NERV
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -293 M | 1.44 M | -30 M | -32.1 M | -49.9 M | 1.94 M | -72.2 M | -50.2 M | -31.5 M | -31 M | -27.1 M | -56.9 M | -3.26 M | -1.58 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 M | -293 M | -48.3 M |
Quarterly Net Income Minerva Neurosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.74 M | -3.26 M | -3.75 M | - | 22.5 M | -8.23 M | -8.57 M | - | -7.82 M | -6.19 M | -6.97 M | - | -6.9 M | -8.72 M | -9.76 M | - | -9.21 M | -10.6 M | -8.8 M | -7.32 M | -8.11 M | 29.5 M | -12.2 M | -29.9 M | -14 M | -12.5 M | -15.8 M | -13.2 M | -12 M | -12.5 M | -12.4 M | 162 K | -11.3 M | -9.78 M | -10.6 M | -9.4 M | -8.42 M | -5.21 M | -8 M | -8.44 M | -5.94 M | -6.61 M | -6.09 M | -7.44 M | -27.2 M | -19.4 M | -2.94 M | -2.13 M | -488 K | -376 K | -271 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29.5 M | -29.9 M | -7.43 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 5.15 | 15.21 % | $ 12.4 B |  Australia |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M |  USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-24.2 M | $ 6.51 | -2.54 % | $ 64.4 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 22.92 | 0.17 % | $ 1.07 B | USA |
 |
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 105.19 | 2.21 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 3.0 | -1.32 % | $ 4.94 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | Britain |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-5.34 M | $ 1.43 | 1.78 % | $ 368 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.24 | -1.85 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.47 | -0.24 % | $ 3.11 B | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 4.99 | 0.6 % | $ 804 M | Britain |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.58 | -1.25 % | $ 420 M | Britain |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 1.2 | 4.35 % | $ 14.6 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
-168 M | $ 3.31 | -3.92 % | $ 333 M | USA |
 |
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-9.74 M | $ 6.73 | -0.88 % | $ 192 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B | USA |
 |
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
17.4 M | - | -0.88 % | $ 598 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
ContraFect Corporation
CFRX
|
-65.2 M | - | -5.16 % | $ 5.39 M | USA |